Back to Top Skip to main content

DTRA contributes to historic Ebola vaccine effort

Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz) Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz)

Recommended Content:

Immunization Healthcare | Immunizations | Global Emerging Infections Surveillance | Global Health Engagement | Global Health Engagement

FORT BELVOIR, Va. — The team of researchers and program managers at the Defense Threat Reduction Agency (DTRA) that has worked to counter the threat of the Ebola Virus Disease (EVD) welcomed the announcement of the U.S. Food and Drug Administration’s (FDA) approval of the vaccine, Ervebo ®, to the pharmaceutical company Merck & Co., Inc., December 19, 2019.

The approval of the vaccine represents the culmination of nearly two decades of efforts by a host of teams from across the public and private sectors such as DTRA and Merck, international partners in North America, Europe and Africa, and non-governmental and international organizations. The World Health Organization (WHO) describes EVD as a rare but severe hemorrhagic fever. EVD has killed thousands over the course of outbreaks, primarily in sub-Saharan Africa, since it first appeared in the 1970s.

DTRA, a Department of Defense combat support agency that identifies and combats biological threats as part of its mission to counter weapons of mass destruction (WMD), began its work on the vaccine in 2014 during an especially deadly outbreak in West Africa. The outbreak made clear the danger EVD posed to U.S. national security interests abroad, as well as to the U.S. domestic population in the event of a pandemic. To counter the threat, DTRA quickly initiated a strategy to get a vaccine approved. The combat support agency coordinated a series of investment efforts and partnerships to deliver a baseline platform for a viable vaccine candidate to mitigate the spread of the deadly disease.

“DTRA’s agile contracting, and well-placed contacts throughout government, academia, and industry allowed DTRA to form partnerships and guide development of this vaccine from the early stages of development, through crucial preclinical, and critical phase 1 clinical safety trials to the actual phase 2 clinical efficacy trial that demonstrated effectiveness of this vaccine during the outbreak,” said L. Revell Phillips Ph.D., a member of DTRA’s research and development team.

DTRA’s pioneering approach started with a contract to BioProtection Systems, a small biotech company. DTRA and BioProtection Systems partnered with Public Health Agency Canada, who began developing the vaccine in 2001, to accelerate its development. With these three teams working together, the vaccine progressed to a series of nonclinical and clinical studies conducted at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) and Walter Reed Army Institute of Research (WRAIR) defense laboratories.

As the effort evolved, DTRA leveraged its USAMRIID partner’s research capacity, resulting in international partnering agreements with the WHO. DTRA also coordinated with teams across the U.S. government as development of the vaccine progressed. The efforts of this research and development consortium produced viable data that would be transitioned to next-level partners.

“We exercised our ability to develop partnerships for a relevant need, which was critical in transitioning medical countermeasures to our advanced developers at the speed of relevancy,” said Army Maj. Jeffrey Froude, DTRA’s program manager for the EVD Vaccine.

Froude explained that DTRA bolstered its research and development investments through two key U.S. governmental partners. First, DTRA worked closely with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for advanced trials and manufacturing activities. Second, DTRA teamed with the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the task of immunoassay development. For that development effort, JPEO-CBRND’s, office of the Joint Program Manager for CBRN Medical took the lead.

Following several years of coordinated research and development efforts by the coalition of partners, the promising vaccine candidate transitioned to next-level partners BARDA and Merck for more advanced human clinical trials and product manufacturing of the EVD vaccine.

“This vaccine’s rapid progress is a testament to the power of partnerships among government agencies and with the private sector,” said BARDA director Rick Bright.

Next-level partner BARDA and Merck, served as the transition point to conduct more advanced human clinical trials and product manufacturing on the Ebola vaccine with the Joint Program Executive office (JPEO) providing a testing capability that allowed Merck to test human and non-human primate samples. The Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM-CBRN), Army Col. Ryan Eckmeier, stated that this “interagency partnership from the beginning was critical to advancing this vaccine product.”

Merck’s expertise with licensing and manufacturing was instrumental in advancing the vaccine. The pharmaceutical giant partnered with the WHO, United Nations International Children's Emergency Fund, and Gavi Vaccine Alliance, among others, to strategize on how to best implement future public health preparedness and response efforts against EVD.

“We share in this achievement, and thank you all personally for your amazing support over the last five years,” said Beth-Ann G. Coller, executive director of Merck’s vaccine team in a note to the DTRA team. “This has truly been a journey and one that we are proud to have shared with our colleagues in DoD. Without the early and continued support of DTRA we would not be here today.”

DTRA continues to leverage its successful partnerships as the agency works to develop future countermeasures. DTRA and BARDA have active partnering agreements to develop vaccine and therapeutic medical countermeasures to address a diverse range of viral and bacterial infectious disease threats. Efforts will use a similar model to the one that supported development and approval of the EVD vaccine.

“As DTRA moves forward to new challenges, we will leverage continued utilization of the Ebola vaccine model, using a diverse range of ways that we can work with our academic, international, interagency and industrial partners through grants, contracts and other transaction authorities,” said Froude. “We have a proven paradigm on how to efficiently advance medical countermeasures working with our U.S. government partners in these endeavors.”

Disclaimer: Re-published content may be edited for length and clarity. Read original post.

You also may be interested in...

2019-nCoV Surveillance Summary #4

Report
2/13/2020

From mid-DEC 2019 to 13 FEB 2020, 59,822 confirmed cases of COVID-19, including1,367 deaths (case fatality proportion 2.3%), have been reported in mainland China. On 12 FEB, the Chinese government reported asubstantial increase in cases (+15,074) and deaths (+253). This is due to an expanded case definition (applicable only in Hubei Province) that includes clinically-diagnosed cases in addition to individuals testing positive via PCR. Additionally, 525 confirmed cases have been reported in 27 countries and regions outside of mainland China, including USINDOPACOM (15), USEUCOM (9), USNORTHCOM 2), and USCENTCOM (1).

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries

2019-nCoV Surveillance Summary #3

Report
2/10/2020

From mid-DEC to 6 FEB, 28,085 confirmed cases of infection with a novel coronavirus (2019-nCoV), including 565 deaths (case fatality proportion 2.0%) have been reported in mainland China. Additionally, 259 confirmed cases have been reported in 27 countries and regions outside of mainland China, including 15 countries/regions in USINDOPACOM, nine in USEUCOM, two in USNORTHCOM, and one in USCENTCOM.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries

MHS prepared to support interagency coronavirus response

Article
2/6/2020
Airmen assist one another in donning their personal protective equipment, while on-board an Air Force C-17 Globemaster III during transportation isolation system training at Joint Base Charleston, South Carolina. Engineered and implemented after the Ebola virus outbreak in 2014, the TIS is an enclosure the Department of Defense can use to safely transport patients with diseases like novel coronavirus. (U.S. Air Force photo by Senior Airman Cody R. Miller)

From R&D to force health protection, MHS protects DoD personnel and families

Recommended Content:

Global Health Engagement | Public Health | Coronavirus

2019-nCoV Surveillance Summary #1

Report
2/4/2020

From mid-DEC to 24 JAN, Chinese health officials have reported 830 cases of infection (25 deaths, case fatality proportion 3%) with a novel coronavirus (2019-nCoV)in mainland China (29 provinces), with the majority (56%) of cases reported from the city of Wuhan in Hubei Province, the presumed epicenter of the outbreak.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries

2019-nCoV Surveillance Summary #2

Report
2/4/2020

From mid-DEC to 30 JAN, 8,124 cases of infection with a novel coronavirus (2019-nCoV), including171 deaths (case fatality proportion 2.1%) have been reported in mainland China. Additionally, 112 cases have been reported in 21 countries and regions outside of mainland China, including 15 countries/regions in USINDOPACOM, three in USEUCOM, two in USNORTHCOM, and one in USCENTCOM.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries

DoD releases guidance to protect forces from novel coronavirus

Article
1/31/2020
The novel coronavirus is a variant of other coronaviruses, such as this colorized transmission electron micrograph of Middle East respiratory syndrome (MERS) virus particles (blue) found near the periphery of an infected VERO E6 cell (yellow). Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Maryland. (Photo by NIAID)

Basic infection controls offer best defense against illness

Recommended Content:

Global Health Engagement | Public Health | Coronavirus

Sorry flu, not this year

Article
1/27/2020
U.S. Air Force Kathryn Klein, right, an aerospace medical service specialist with 182nd Medical Group, Illinois Air National Guard, administers an influenza vaccination during drill weekend at the 182nd Airlift Wing in Peoria, Ill., Dec. 8, 2019. According to the Centers for Disease Control and Prevention, the flu is a contagious respiratory illness caused by influenza viruses, and the best prevention is getting a flu vaccine each year. (U.S. Air National Guard photo by Senior Airman Paul R. Helmig II)

The Defense Logistics Agency Troop Support Medical supply chain teamed with Department of Defense partners to provide 3.4 million doses of the influenza vaccine to service members, dependents and retirees.

Recommended Content:

Immunization Healthcare | Health Readiness | Influenza Summary and Reports | Influenza, Northern Hemisphere | Seasonal Influenza Resource Center 2019-20

Coronavirus: What providers, patients should know

Article
1/24/2020
A dental assistant with the 319th Medical Group, demonstrates proper sanitary procedure by putting on a face mask at the medical treatment facility on Grand Forks Air Force Base, N.D.

What to do now that virus has appeared in U.S.

Recommended Content:

Global Health Engagement | Public Health | Global Health Engagement | Coronavirus

Mid-season flu activity increase: How to keep healthy

Article
1/22/2020
Navy Hospital Corpsman Kenny Liu, from San Jose, assigned to USS Gerald R. Ford's medical department, prepares a needle with a flu vaccination in the ship's hangar bay. (U.S. Navy photo by Mass Communication Specialist Seaman Apprentice Angel Thuy Jaskuloski)

Despite reports of increased flu activity in the U.S., the Military Health System remains vigilant

Recommended Content:

Immunization Healthcare | Influenza Summary and Reports | Health Readiness | Influenza, Northern Hemisphere | Influenza, Southern Hemisphere | Vaccine Recommendations | Vaccine-Preventable Diseases | Armed Forces Health Surveillance Branch

HPV vaccine age limit raised by FDA to age 45

Article
1/14/2020
https://www.nfid.org/infectious-diseases/hpv/ Recent CDC and FDA guidance recommends that men and women up to 45 years of age get vaccinated to protect against the Human papillomavirus (HPV). HPV is the most common sexually transmitted infection and can cause certain cancers and genital warts. More than 14 million new HPV infections occur in the U.S. each year, and about 80 percent of sexually active men and women are infected with HPV at some point in their lives. (National Foundation for Infectious Diseases image)

HPV shot protects against a host of diseases in men, women

Recommended Content:

Conditions and Treatments | Health Readiness | Preventive Health | Men's Health | Women's Health | Immunization Healthcare | Vaccine-Preventable Diseases | Vaccine Recommendations

Air Force International Health Specialist builds medical capability in Iraq

Article
12/30/2019
U.S. Air Force Lt. Col. Jessica Cowden, Infectious Disease Programs chief with the Defense Institute for Medical Operations, Joint Base San Antonio-Lackland, Texas, poses for a photo with the NATO Mission Iraq Embedded Training Team during the Combined Joint Task Force - Operation Inherent Resolve, June 25, 2019. (Photo By Josh Mahler)

Cowden’s work facilitated the exchange of medical knowledge and practices between Kurdish and Iraqi security forces.

Recommended Content:

Global Health Engagement | Global Health Engagement

Global Health Engagement strengthens partnerships

Article
12/20/2019
U.S. Navy Capt. Michael Sullivan, a pediatrician assigned to the hospital ship USNS Comfort, gives a sticker to a two-year-old boy after examining his skin infection at a temporary medical treatment site in Port-Au-Prince, Haiti. During Comfort’s deployment, the crew worked with health and government partners in Central America, South America, and the Caribbean to provide care on the ship and at a temporary medical treatment site, helping to relieve pressure on national medical systems, including those strained by an increase in cross-border migrants. (U.S. Navy Photo by Mass Communication Specialist 3rd Class Maria G. Llanos)

GHE advances U.S. national security interests around the world

Recommended Content:

Global Health Engagement | Year in Review - A Look Forward | Global Health Engagement

Ship-based Global Health Engagement

Article
12/4/2019
Navy Capt. Heather King, executive director of the TriService Nursing Research Program at the Uniformed Services University, details the process of ship-based global health engagement missions during the October 22, 2019, Medical Museum Science Café titled "Ship-Based Global Health Engagement Missions: Expanding Global Partnerships" at the National Museum of Health and Medicine in Silver Spring, Maryland. (NMHM photo)

Global health engagement is an important priority for military medicine

Recommended Content:

Global Health Engagement | National Museum of Health and Medicine | Global Health Engagement

Network of researchers advancing warfighter readiness

Article
12/4/2019
Air Force Maj. Gen. Lee Payne, the assistant director for Combat Support at DHA, delivered the keynote address at the Global Emerging Infections Surveillance Scientific and Programmatic Advancement Meeting, GSPAM. He emphasized the importance of Force Health Protection measures and linked the GEIS mission to DHA’s combat support mission. (DoD photo)

In fiscal year 2020, GEIS awarded approximately $60 million to more than 20 DoD laboratories and U.S. government partners

Recommended Content:

Combat Support | Global Health Engagement | Global Emerging Infections Surveillance

World AIDS Day puts spotlight on landmark DoD study

Article
12/2/2019
Dr. John Mascola, director of the National Institutes of Health Vaccine Research Center, discusses HIV vaccine progress at the Walter Reed Army Institute of Research, Nov. 26, during a World AIDS Day commemoration.  (U.S. Army photo)

Vaccine study shows infection risk lowered by 31 percent, offering hope for future

Recommended Content:

Immunization Healthcare | Research and Innovation | Global Health Engagement | Year in Review - A Look Forward
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 12

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.